What is HC Wainwright’s Estimate for JSPR Q1 Earnings?

Jasper Therapeutics, Inc. (NASDAQ:JSPR) – Investment analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Jasper Therapeutics in a research note issued on Wednesday, January 8th. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings of ($1.48) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for Jasper Therapeutics’ current full-year earnings is ($4.47) per share. HC Wainwright also issued estimates for Jasper Therapeutics’ Q2 2025 earnings at ($1.63) EPS, Q3 2025 earnings at ($1.78) EPS, Q4 2025 earnings at ($1.93) EPS, FY2025 earnings at ($6.83) EPS, FY2026 earnings at ($8.17) EPS, FY2027 earnings at ($9.50) EPS and FY2028 earnings at ($10.61) EPS.

Other research analysts also recently issued reports about the company. BMO Capital Markets assumed coverage on Jasper Therapeutics in a research note on Friday, December 6th. They set an “outperform” rating and a $63.00 price objective for the company. JMP Securities restated a “market outperform” rating and issued a $70.00 price target on shares of Jasper Therapeutics in a research note on Monday, January 6th. Finally, Royal Bank of Canada cut their target price on Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating on the stock in a research note on Thursday, January 9th. Ten investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $67.75.

Jasper Therapeutics Stock Performance

JSPR opened at $5.87 on Monday. Jasper Therapeutics has a 1-year low of $5.85 and a 1-year high of $31.01. The company has a 50-day moving average of $20.78 and a 200-day moving average of $20.04. The company has a market capitalization of $88.06 million, a P/E ratio of -1.24 and a beta of 2.18.

Institutional Trading of Jasper Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Braidwell LP purchased a new stake in shares of Jasper Therapeutics in the 3rd quarter valued at approximately $9,091,000. Ally Bridge Group NY LLC grew its holdings in shares of Jasper Therapeutics by 82.7% during the third quarter. Ally Bridge Group NY LLC now owns 399,466 shares of the company’s stock valued at $7,514,000 after buying an additional 180,852 shares in the last quarter. Samsara BioCapital LLC raised its position in Jasper Therapeutics by 11.4% during the third quarter. Samsara BioCapital LLC now owns 584,642 shares of the company’s stock valued at $10,997,000 after buying an additional 59,642 shares during the period. FMR LLC acquired a new stake in Jasper Therapeutics during the 3rd quarter worth about $722,000. Finally, Bank of New York Mellon Corp purchased a new position in Jasper Therapeutics during the 2nd quarter valued at about $740,000. Institutional investors and hedge funds own 79.85% of the company’s stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.